AVXL vs. IMTX, NVAX, EDIT, ALEC, TWST, HLVX, ALLO, RGNX, FDMT, and MESO
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Immatics (IMTX), Novavax (NVAX), Editas Medicine (EDIT), Alector (ALEC), Twist Bioscience (TWST), HilleVax (HLVX), Allogene Therapeutics (ALLO), REGENXBIO (RGNX), 4D Molecular Therapeutics (FDMT), and Mesoblast (MESO). These companies are all part of the "biological products, except diagnostic" industry.
Anavex Life Sciences vs.
Anavex Life Sciences (NASDAQ:AVXL) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.
Immatics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences presently has a consensus target price of $42.60, indicating a potential upside of 357.08%. Immatics has a consensus target price of $19.75, indicating a potential upside of 100.51%. Given Anavex Life Sciences' higher possible upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Immatics.
Anavex Life Sciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Anavex Life Sciences has a net margin of 0.00% compared to Immatics' net margin of -85.93%. Anavex Life Sciences' return on equity of -36.78% beat Immatics' return on equity.
31.2% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 29.1% of Immatics shares are held by institutional investors. 11.6% of Anavex Life Sciences shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Immatics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Immatics and 5 mentions for Anavex Life Sciences. Immatics' average media sentiment score of 0.82 beat Anavex Life Sciences' score of 0.45 indicating that Immatics is being referred to more favorably in the news media.
Anavex Life Sciences received 396 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 74.20% of users gave Anavex Life Sciences an outperform vote while only 70.59% of users gave Immatics an outperform vote.
Summary
Anavex Life Sciences beats Immatics on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Anavex Life Sciences Competitors List
Related Companies and Tools